Neuphoria Therapeutics (NEUP) Q3 2025 earnings summary

Executive summary

• Achieved net income of $11.3 million for the quarter and $8.5 million for the nine months ended March 31, 2025, driven by milestone payments from Merck and Carina Biotech agreements.

• Completed redomiciliation from Australia to Delaware, with Bionomics becoming a wholly owned subsidiary and Neuphoria as the successor issuer.

• Lead candidate BNC210 advanced in Phase 3 trials for PTSD and SAD, with enrollment ongoing in the AFFIRM-1 trial for social anxiety disorder and topline data expected in Q3 2025.

• Strategic partnership with Merck continues, advancing MK-1167 in Phase 2 trial for Alzheimer's disease therapies.

• Achieved steady progress in clinical pipeline during Q1 2025, with key programs advancing as planned.

Financial highlights

• Revenue for the quarter was $15 million, up from $0 in the prior year, due to a Merck milestone payment.

• Operating expenses for the quarter were $3.0 million, up 26% year-over-year, mainly from increased R&D and G&A costs.

• Net income per share was $6.55 (basic and diluted) for the quarter, compared to a loss of $2.83 per share last year.

• Cash and cash equivalents totaled $17.0 million as of March 31, 2025.

• Cash runway extends into Q3 2026, supporting ongoing and planned clinical activities.

Outlook and guidance

• Existing cash and equivalents expected to fund operations into Q1 fiscal 2027.

• Topline results from Phase 3 AFFIRM-1 trial for BNC210 in social anxiety disorder anticipated in Q3 2025.

• Management anticipates continued net losses as R&D and administrative expenses increase with clinical development and U.S. operations.

• Planning underway for Phase 2b SYMPHONY trial for BNC210 in PTSD, contingent on capital requirements and Phase 3 readout.